<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333228</url>
  </required_header>
  <id_info>
    <org_study_id>EPC/CIRR</org_study_id>
    <nct_id>NCT01333228</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Efficacy of Autologous Bone Marrow-derived Endothelial Progenitor Cells in Advanced Liver Cirrhosis</brief_title>
  <official_title>Pilot Clinical Trial (Phase I/II) to Evaluate Safety and Therapeutic Effects of the Administration of Autologous Bone Marrow-derived EPCs in Patients With Advanced Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation Ramon Areces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelial Progenitor Cells (EPC) represent a small cellular population of bone marrow and
      peripheral blood cells. EPCs are recruited into injured tissues and play an important role in
      regeneration and reparation. Experimental and clinical data suggest that EPCs have
      hepatoprotective activity and could improve liver regeneration during acute and chronic liver
      injury. The aim of this project is to evaluate the safety and therapeutic effects of
      autologous bone marrow-derived EPCs, when administered through the hepatic artery of patients
      with advanced liver cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and tolerability</measure>
    <time_frame>12 months</time_frame>
    <description>The safety of the administration of autologous bone marrow-derived EPC in patients with advanced cirrhosis will be evaluated by anamnesis, physical examination, hematological and biochemical variables and imaging examination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of liver function test as a measure of the effect on liver function</measure>
    <time_frame>12 months</time_frame>
    <description>Determination of liver function test (aminotransferases,albumin, bilirubin and protrombin time) and calculation of Model for End-Stage Liver Disease (MELD) and Chil-Pugh scores. Differences in these variables compared to baseline will be considered as a measure of the effect on liver function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on portal hypertension</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in Hepatic Venous Pressure Gradient (HVPG) will be used to assess the effect on portal hypertension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on complications of liver cirrhosis</measure>
    <time_frame>12 months</time_frame>
    <description>Ascitis grade, episodes of upper gastrointestinal bleeding as well as of episodes of hepatic encephalopathy will be used as a measure of the effect of the treatment on the complications of liver cirrhosis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Endothelial Progenitors Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous bone marrow-derived endothelial progenitor cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous bone marrow-derived endothelial progenitor cells</intervention_name>
    <description>Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells</description>
    <arm_group_label>Endothelial Progenitors Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis (Child-Pugh 8 or above).

          -  Ability to sign informed consent

        Exclusion Criteria:

          -  Age &lt;18 or &gt;75

          -  Variceal bleeding or severe infection within the past 30 days before screening

          -  Chronic encephalopathy preventing the ability to sign informed consent (it could be
             done by legal representant of the patient) and/or the ability to follow the study
             protocol

          -  Hepatocellular carcinoma (previous or current)

          -  Any current or previous malignancy (within 5 years before the inclusion) except &quot;in
             situ&quot; tumors or skin basal cell carcinomas

          -  Any severe extrahepatic disease during the past 30 days before the inclusion

          -  Any current decompensated chronic disease

          -  Any contraindication for the examinations of the clinical protocol (medullar
             aspiration, arteriography, HVPG measurement)

          -  Any other condition that could negatively affect the compliance with the protocol

          -  Pregnant or breast-feeding women

          -  Participation in a trial of an experimental drug or device within 30 days before
             screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Quiroga, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liver Unit, Clinica Universidad de Navarra/Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd)(Pamplona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jesus Prieto, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Liver Unit, Clinica Universidad de Navarra/Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd)/Centro de Investigación Medica Aplicada (CIMA)(Pamplona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Delia D'Avola, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Liver Unit, Clinica Universidad de Navarra/Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd)(Pamplona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Ignacio Herrero, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Liver Unit, Clinica Universidad de Navarra/Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd)(Pamplona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno Sangro, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Liver Unit, Clinica Universidad de Navarra/Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd)(Pamplona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Veronica Fernandez Ruiz, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centro de Investigación Medica Aplicada (CIMA)(Pamplona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Perez Calvo, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hematology, Clinica Universidad de Navarra (Pamplona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercedes Iñarrairaegui, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Liver Unit, Clinica Universidad de Navarra/Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd)(Pamplona-Spain)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose Ignacio Bilbao, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radiology, Clinica Universidad de Navarra (Pamplona-Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.cun.es</url>
    <description>Clinica Universidad de Navarra</description>
  </link>
  <link>
    <url>http://www.cima.es</url>
    <description>Centro de Investigación Medica Aplicada (CIMA)</description>
  </link>
  <link>
    <url>http://www.ciberehd.org</url>
    <description>Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>May 25, 2015</last_update_submitted>
  <last_update_submitted_qc>May 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

